logo.jpg
Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
August 17, 2023 08:05 ET | Processa Pharmaceuticals, Inc.
Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER,...
George Ng photo -2014BSD 061ret - Ng
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
August 08, 2023 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focusing on developing the next...
LIXTE.jpg
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
October 13, 2022 08:30 ET | Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and...
LIXTE.jpg
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
June 21, 2022 08:30 ET | Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies,...
LIXTE.jpg
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
May 12, 2021 09:35 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve...
logo.png
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 07, 2020 09:02 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
logo.png
Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
March 07, 2019 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Tuesday, March 12 at 8:30 a.m. ET - Norwood, MA, March 07, 2019 (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
logo.png
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
March 04, 2019 09:15 ET | Corbus Pharmaceuticals Holdings, Inc.
Advances commercialization strategy for lenabasum ahead of data readouts of key registrational studies in 2020, and potential U.S. Food and Drug Administration (“FDA”) approval and launch in 2021Mr....
logo.png
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 24, 2019 16:01 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s...
CRBP-300-196.png
Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
November 05, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Nov. 8th at 8:30 AM ET - Norwood, MA, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...